ReviewAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Posterior Scleral Reinforcement to Prevent Progression of High Myopia.
Review in Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- [Research progress and applications of biologically derived materials in scleral reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- The mechanistic study of injectable hydrogel loaded with BMSC-exosomes in regulating the TGF-β/MMP axis to inhibit experimental myopia model.Materials today. Bio · 2026Article
- Degradable Suture-Free Scaffold to Induce Therapeutic Ridge Formation and to Control Eye Elongation: A Potential Treatment for Pathological Myopia.Translational vision science & technology · 2026Article
- Comparison of posterior scleral reinforcement surgery and repeated low-level red-light therapy in controlling high and super high myopia in Chinese children.International journal of ophthalmology · 2026Article
- Pathologic myopia as a concurrent condition in Pierre Robin sequence: a case report and literature review.Frontiers in medicine · 2026Article
- Hypoxia-induced OPN5 expression is associated with matrix-preserving responses in human scleral fibroblasts.Frontiers in neuroscience · 2026Article
- Non-invasive low-level red-light therapy for axial length control in pediatric extreme myopia.iScience · 2025Article
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Intraocular pressure is a promising target for myopia control.Journal of translational medicine · 2025Article
- Correlation of contrast sensitivity at low spatial frequencies with myopic shift in Chinese children.BMC ophthalmology · 2025Article
- An Evidence-Based Narrative Review of Scleral Hypoxia Theory in Myopia: From Mechanisms to Treatments.International journal of molecular sciences · 2025Review
- Collagen is crucial target protein for scleral remodeling and biomechanical change in myopia progression and control.Heliyon · 2024Review
- Computational modelling of scleral photocrosslinking: from rat to minipig to human.Journal of the Royal Society, Interface · 2024Article
- Nonlinear pathological trajectory of a high-myopia C57/BL6J mouse model induced by form deprivation.Frontiers in physiology · 2024Article
- Observation of the effect of posterior scleral reinforcement combined with orthokeratology and 0.01% atropine in the treatment of congenital myopia: a case report.BMC ophthalmology · 2023Article
- Understanding Posterior Staphyloma in Pathologic Myopia: Current Overview, New Input, and Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Evaluation of new robust silk fibroin hydrogels for posterior scleral reinforcement in rabbits.Frontiers in bioengineering and biotechnology · 2023Article
- Posterior scleral reinforcement for the treatment of myopic traction maculopathy.BMC ophthalmology · 2022Article
- Scleral Cross-Linking in Form-Deprivation Myopic Guinea Pig Eyes Leads to Glaucomatous Changes.Investigative ophthalmology & visual science · 2022Article
- Long-term outcome of pathologic myopic foveoschisis treated with posterior scleral reinforcement followed by vitrectomy.International journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyopia has become a global public health problem. High myopia is linked to pathologic myopia (PM). As the severity of myopia increases, excessive axial elongation of the globe exerts a biomechanical stretch on the posterior pole, followed by a series of retinopathy which can lead to marked visual impairment. Posterior scleral reinforcement (PSR) is the only way that may have the potential to prevent the progression of axial elongation. Some scholars expressed satisfaction with the efficacy and safety of PSR. In contrast, other surgeons had negative conclusions on the outcomes for the surgery.
objectivesThe aims of this review are to provide an update on the current knowledge of posterior scleral reinforcement to prevent progression of high myopia and to discuss clinical trials examining the potential utility of PSR in treating this disease.
methodsWe searched Ovid MEDLINE, Embase, PubMed and China National Knowledge Infrastructure (CNKI) (all years to 1 July 2019). We also conducted a gray literature search and handsearched reference lists of included studies and pertinent review articles.
results26 clinical trials were included. 20 trials were designed as only one eye of each patient had posterior scleral reinforcement surgery. After 3 to 5 years of follow-up, the results are very satisfactory. 6 randomized controlled trials, which have conservatively treated groups, showed statistically significant differences between the eyeball axial length progression in the study group and the control group, where surgery was not performed. Most clinical trials reached a positive influence. But the efficacy of different clinical trials varies greatly.
conclusionsPSR, is safe and effective to slowdown myopia progression, especially for high myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.